History and future perspectives of treating asthma as a systemic and small airways disease

Respiratory Medicine

Volumn 95, Issue 9, 2001, Pages 703-719

  Bjermer, L ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Asthma; Inflammation; Leukotriene receptor antagonists; Small airways; Systemic

Indexed keywords

ADRENALIN; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CORTISONE; CROMOGLYCATE DISODIUM; FLUTICASONE; FORMOTEROL; HYDROCORTISONE; IMMUNOGLOBULIN E ANTIBODY; ISOPRENALINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; NEDOCROMIL SODIUM; PREDNISOLONE; PREDNISONE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE;

AIRWAY DYNAMICS; ASTHMA; BRONCHODILATATION; CUSHING SYNDROME; DRUG PENETRATION; DYSPHONIA; FRACTURE; GLAUCOMA; GROWTH INHIBITION; HEART PALPITATION; HISTORY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATORY DISEASE; LUNG FUNCTION; MEASUREMENT; MENTAL DISEASE; METHODOLOGY; MUSCLE ATROPHY; OSTEOPOROSIS; PEPTIC ULCER; PRIORITY JOURNAL; RESPIRATORY TRACT PARAMETERS; RESTLESSNESS; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SMALL AIRWAY DISEASE; SYSTEMIC DISEASE; TACHYCARDIA; TREATMENT PLANNING; TREMOR; WATER RETENTION;

EID: 0034803992     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2001.1148     Document Type: Review

References (192)

1. A history of asthma. The FitzPatrick Lecture 1987
2. Introduction
3. Account of the good effects from inhaling the smoke of several species of Datura, especially the Datura fastuosa, in asthma
4. Definitions and classification of chronic bronchitis, asthma, and pulmonary emphysema
5. What is the nature of asthma and where are the therapeutic targets?
6. The pathology of bronchial asthma
7. The pathology of asthma, with special reference to changes in the bronchial mucosa
8. Causes of death and pathologic findings in 304 cases of bronchial asthma
9. A comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis and in emphysema
10. The mechanics of airway narrowing in asthma
11. Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma
12. Global strategy for Asthma Management and Prevention
13. Inflammation of small airways in asthma
14. Targeting drug delivery and the small airways in asthma
15. Asthma and allergic rhinitis in the same patients
16. Epidemiology and natural history of asthma, allergoic rhinitis and atopic dermatitis (eczema)
17. A 10-year prognosis for childhood allergic rhinitis
18. Asthma and wheezing in the first six years of life
19. Bronchial hyperresponsiveness and airway inflammation markers in nonasthmatics with allergic rhinitis
20. Demonstration of bronchial eosinophil activity in seasonal allergic rhinitis by induced plasma exudation combined with induced sputum
21. Allergic rhinitis and asthma: How important is the link?
22. Asymptomatic bronchial hyperresponsiveness in rhinitis
23. Different prevalence and degree of nonspecific bronchial hyperreactivity between seasonal and perennial rhinitis
24. Is bronchial hyperresponsiveness more frequent in women than in men? A population-based study
25. Seasonal variation in bronchial hyperreactivity (BHR) in allergic patients
26. Seasonal increase of bronchial reactivity in allergic rhinitis
27. Exhaled and nasal NO levels in allergic rhinitis: Relation to sensitization, pollen season and bronchial hyperresponsiveness
28. Eosinophils are a feature of upper and lower airway pathology in non-atopic asthma, irrespective of the presence of rhinitis
29. Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide
30. Exhaled and inhaled NO measurements: Recommendations
31. Exhaled nitric oxide in seasonal allergic rhinitis: Influence of pollen season and therapy
32. Bone marrow events in animal models of allergic inflammation and hyperresponsiveness
33. Systemic aspects of allergic disease: Bone marrow responses
34. The inflammatory response in asthma exacerbation: Changes in circulating eosinophils, basophils and their progenitors
35. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid
36. Increased numbers of circulating basophil progenitors in atopic patients
37. Basophilic cell progenitors, nasal metachromatic cells, and peripheral blood basophils in ragweed-allergic patients
38. Basophils, eosinophils, and mast cells in atopic and nonatopic asthma and in late-phase allergic reactions in the lung and skin
39. Systemic activation of basophils and eosinophils: Markers and consequences
40. Molecular pathology of allergic disease: I. Lower airway disease
41. T lymphocytes in asthma: Bronchial versus peripheral responses
42. Allergen sensitization through the skin induces systemic allergic responses
43. Atopic dermatitis: New insights and opportunities for therapeutic intervention
44. Prognosis of asthma in childhood
45. Bronchial and skin reactivity in asthmatic patients with and without atopic dermatiotis
46. The mechanics of breathing
47. The relevance of site of airway inflammation in asthma and targeted aerosol delivery
48. Resistance of central and peripheral airways measured by a retrograde catheter
49. Site and nature of airway obstruction in chronic obstructive lung disease
50. Treating large and small airways
51. Frequency dependence of compliance as a test for obstruction in the small airways
52. Assessment of airway inflammation in asthma
53. Inflammatory and structural changes in the airways of patients with asthma
54. Acute bronchial asthma. Relations between clinical and physiologic manifestations
55. Peripheral lung resistance in normal and asthmatic subjects
56. Correlation between objective measures of airway calibre and clinical symptoms in asthma: A systematic review of clinical studies
57. Relationship between airway obstruction and respiratory symptoms in adult asthmatics
58. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics
59. Improvement in bronchial asthma not reflected in forced expiratory volume
60. Lung volumes in exacerbations of asthma
61. Site of airway obstruction in pulmonary disease: Direct measurement of intrabronchial pressure
62. Effects of airway calibre on lung delivery of nebulised salbutamol
63. The natural history of asthma in adults: The problem of irreversibility
64. The relations between structural changes in small airways and pulmonary-function tests
65. Variability of closing volume measurements in normal man
66. 2 closing volume test in population studies: Sources of variation and reproducibility
67. The influence of clinical factors on site of airway obstruction in asthma
68. The maximum expiratory flow-volume curve with air and a low-density gas mixture. An analysis of subject and observer variability
69. Diseases of the bronchioles: CT and histopathologic findings
70. Airway hyperreactivity: Assessment with helical thin-section CT
71. Development and testing of image-processing methods for the quantitative assessment of airway hyperresponsiveness from high-resolution CT images
72. Airway wall thickness in patients with near fatal asthma and control groups: Assessment with high resolution computed tomographic scanning
73. Evaluation of airways in obstructive pulmonary disease using high-resolution computed tomography
74. HFA-BDP and its implications for the quiet zone
75. Quantitative computed tomography detects air trapping due to asthma
76. Small airways: A time to revisit?
77. Functional significance of air trapping detected in moderate asthma
78. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: Assessment with functional helical thin-section computed tomography
79. The effect of bronchial obstruction on central airway deposition of a saline aerosol in patients with asthma
80. Changing patterns of aerosol deposition during methacholine bronchoprovocation
81. The distal airways: Are they important in asthma?
82. Small airway inflammation and asthma
83. Cellular infiltration of the airways in asthma of varying severity
84. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics
85. A model of airway narrowing in asthma and in chronic obstructive pulmonary disease
86. Small airways dimensions in asthma and in chronic obstructive pulmonary disease
87. Inflammatory cell distribution within and along asthmatic airways
88. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo
89. Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes
90. Airways inflammation in nocturnal asthma
91. Small airway and alveolar tissue changes in nocturnal asthma
92. Alveolar tissue inflammation in asthma
93. Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night
94. Keeping children with exercise-induced asthma active
95. Exercise-induced asthma
96. Peripheral airways responsiveness to cool, dry air in normal and asthmatic individuals
97. Effects of cool, dry air stimulation on peripheral lung mechanics in asthma
98. A 15-year follow-up study of ventilatory function in adults with asthma
99. Rate of decline of lung function in subjects with asthma
100. Decline of lung function in adults with bronchial asthma
101. Long-term effects of budesonide or nedocromil in children with asthma
102. The structure of large and small airways in nonfatal and fatal asthma
103. The lack of distensibility of asthmatic airways
104. High-resolution computed tomography in patients with bronchial asthma: Correlation with clinical features, pulmonary functions and bronchial hyperresponsiveness
105. The shape of the dose-response curve to histamine in asthmatic and normal subjects
106. Airway hyperresponsiveness in asthma: A problem of limited smooth muscle relaxation with inspiration
107. The use of adrenal substance in the treatment of asthma
108. On the medical history of xanthines and other remedies for asthma: A tribute to HH Salter
109. Pharmacological therapy for asthma: Overview and historical perspective
110. Current therapies for asthma. Promise and limitations
111. The effect of cortisone on bronchial asthma and hay fever occurring in subjects sensitive to ragweed pollen
112. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention: A Pocket Guide for Physicians and Nurses
113. Increased ventilation caused by improved diaphragmatic efficiency during aminophylline infusion
114. Effects of methylxantines on airway mucociliary function
115. Increased hypoxic ventilatory drive due to adminstration of aminophylline in normal men
116. Single-dose slow-release aminophylline at night prevents nocturnal asthma
117. Nocturnal asthma: Slow-release terbutaline versus slow-release theophylline therapy
118. Overnight theophylline concentrations and effects on sleep and lung function in chronic obstructive pulmonary disease
119. Observations on recent increase in mortality from asthma
120. Beta-adrenergic bronchodilators
121. Questions about inhaled beta 2-adrenoceptor agonists in asthma
122. The use of beta-agonists and the risk of death and near death from asthma
123. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists
124. Regular inhaled beta-agonist treatment in bronchial asthma
125. Canadian asthma consensus report, 1999
126. Beta-adrenergic receptors and their regulation
127. Tolerance with beta 2-adrenoceptor agonists: Time for reappraisal
128. Effect of inhaled formoterol and budesonide on exacerbations of asthma
129. One year treatment with salmeterol compared with beclomethasone in children with asthma
130. Role of leukotrienes in asthma pathophysiology
131. Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma
132. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma
133. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol
134. Asthma mechanisms, determinants of severity and treatment: The role of nedocromil sodium
135. Action of cortisone by aerosol method in the treatment of bronchial asthma
136. Expert panel report 2: Guidelines for the diagnosis and management of asthma
137. Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function
138. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler
139. Comparison of twice daily administration of a new corticosteroid budesonide with beclomethasone dipropionate four times daily in the treatment of chronic asthma
140. Inhaled glucocorticoids for asthma
141. New perspectives on inhaled drug delivery and systemic bioactivity
142. Patient compliance in a clinical trial with inhaled budesonide in children with mild asthma
143. Potential masking effects of salmeterol on airway inflammation in asthma
144. Dose response to inhaled corticosteroids: Benefits and risks
145. Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation
146. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma
147. Budesonide treatment of moderate and severe asthma in children: A dose-response study
148. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma
149. The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects
150. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial
151. Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. The effects of antiasthmatic treatment with budesonide or terbutaline
152. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double-blind, parallel-group controlled trial
153. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma
154. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma
155. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction
156. Effect of lung function and mode of inhalation on penetration of aerosol into the human lung
157. Inhaled beclomethasone dipropionate downregulates airway lymphocyte activation in atopic asthma
158. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma
159. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study
160. A comparison of low-dose inhaled budesonide plus theophylline and high- dose inhaled budesonide for moderate asthma
161. The problems of treating adolescent asthma: What are the alternatives to inhaled therapy?
162. The relationship between airways inflammation and asthma severity
163. Deposition and clearance of inhaled 18FDG powder in patients with chronic obstructive pulmonary disease
164. Improved delivery of inhaled steroids to the large and small airways
165. A comparison of lung deposition patterns between different asthma inhalers
166. Drug delivery to the small airways
167. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone
168. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol
169. Prevention of asthma exacerbation by HFA flunisolide in adults and adolescents with mild-to-moderate asthma
170. Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma
171. Clinical pharmacology of corticosteroids in bronchial asthma
172. Three-dimensional description of pulmonary deposition of inhaled aerosol using data from multimodality imaging
173. Noncompliance with asthma therapy-Are there solutions?
174. Comparison of patients' compliance with prescribed oral and inhaled asthma medications
175. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma
176. Current treatment of asthma-focus on leukotrienes
177. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of 'one linked airway disease'
178. Expression of the cysteinyl leukotriene I receptor in normal human lung and peripheral blood leukocytes
179. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized, double-blind trial
180. Montelukast added to inhaled beclomethasone in treatment of asthma
181. Montelukast added to budesonide in children with asthma: A randomized, double-blind, crossover study
182. Treatment of allergic asthma with monoclonal anti-IgE antibody
183. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response
184. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects
185. Experimental treatments for asthma
186. DNA-based immunization for asthma